The human papillomavirus is responsible for cervix cancer, gene mutations and subsequent hereditary diseases. It is therefore important that doctors can diagnose the infection using a cheap, fast and patient-friendly diagnostic tool. The EU-funded team behind the project 'Enhanced sensitivity nanotechnology-based multiplexed bioassay platform for diagnostic applications' (Nano-Mubiop) aims to provide such a tool using non-biological particles in the nanometre size range. The researchers explain that the 'interaction between non-biological nano-particles and the target biological system allows the detection of the target without any DNA (Deoxyribonucleic acid) amplification stage'. They say that this means 'enhanced diagnostic capabilities' and allows them to overcome many of the limitations of existing diagnostic methods. To begin the development of the new device, the project team firstly defined the technical requirements and specification of the method. Moreover, to ensure it would ultimately be suitable for commercialisation, they also reviewed the US Food and Drink Administration's (FDA's) regulatory procedures. They then moved to the practical development and testing of the new tool, and set up an ethical and medical board to evaluate their results.
Enhanced sensitivity Nanotechnology-based Multiplexed Bioassay Platform for diagnostic applications
Discover other articles in the same domain of application
New products and technologies
6 July 2020